Reemergence of PML in Natalizumab-Treated Patients - New Cases, Same Concerns

被引：69
作者：
Major, Eugene O. [1 ]
机构：
[1] NINDS, Lab Mol Med & Neurosci, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 361卷 / 11期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANTIBODY NATALIZUMAB; CELLS;
D O I：
10.1056/NEJMp0906248
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1041 / 1043
页数：3
相关论文
共 42 条
  • [21] Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCVA® DxSelect™ antibody assay
    Campagnolo, Denise
    Dong, Qunming
    Lee, Lily
    Ho, Pei-Ran
    Amarante, Diogo
    Koendgen, Harold
    JOURNAL OF NEUROVIROLOGY, 2016, 22 (06) : 880 - 881
  • [22] JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients
    Delbue, Serena
    Elia, Francesca
    Carloni, Camilla
    Pecchenini, Valentina
    Franciotta, Diego
    Gastaldi, Matteo
    Colombo, Elena
    Signorini, Lucia
    Carluccio, Silvia
    Bellizzi, Anna
    Bergamaschi, Roberto
    Ferrante, Pasquale
    JOURNAL OF NEUROVIROLOGY, 2015, 21 (06) : 645 - 652
  • [23] Assessment of JC Virus DNA in Blood and Urine from Natalizumab-Treated Patients
    Rudick, Richard A.
    O'Connor, Paul W.
    Polman, Chris H.
    Goodman, Andrew D.
    Ray, Soma S.
    Griffith, Nancy M.
    Jurgensen, Stephanie A.
    Gorelik, Leonid
    Forrestal, Fiona
    Sandrock, Alfred W.
    Goelz, Susan E.
    ANNALS OF NEUROLOGY, 2010, 68 (03) : 304 - 310
  • [24] Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance
    Kagstrom, Stina
    Falt, Anna
    Berglund, Anders
    Piehl, Fredrik
    Olsson, Tomas
    Lycke, Jan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
  • [25] The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis
    Robier, C.
    Amouzadeh-Ghadikolai, O.
    Bregant, C.
    Diez, J.
    Melinz, K.
    Quehenberger, F.
    Quasthoff, S.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (05) : 469 - 474
  • [26] Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy
    Serana, Federico
    Chiarini, Marco
    Sottini, Alessandra
    Bertoli, Diego
    Giustini, Viviana
    Tessitore, Marion Vaglio
    Caimi, Luigi
    Capra, Ruggero
    Imberti, Luisa
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 277 (1-2) : 6 - 12
  • [27] Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
    Fine, Andrew J.
    Sorbello, Alfred
    Kortepeter, Cindy
    Scarazzini, Linda
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) : 849 - 852
  • [28] Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate
    Scarpazza, Cristina
    Signori, Alessio
    Cosottini, Mirco
    Sormani, Maria Pia
    Gerevini, Simonetta
    Capra, Ruggero
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (10) : 1227 - 1236
  • [29] The use of cytokine signature patterns: separating drug naive, interferon and natalizumab-treated multiple sclerosis patients
    O'Connell, Kara E.
    Mok, Tzehow
    Sweeney, Brian
    Ryan, Aisling M.
    Dev, Kumlesh K.
    AUTOIMMUNITY, 2014, 47 (08) : 505 - 511
  • [30] JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
    Mancuso, Roberta
    Saresella, Marina
    Hernis, Ambra
    Marventano, Ivana
    Ricci, Cristian
    Agostini, Simone
    Rovaris, Marco
    Caputo, Domenico
    Clerici, Mario
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
12345